Arete Therapeutics Secures $13,300,000 Series A Financing

  • Feed Type
  • Date
    5/23/2007
  • Company Name
    Arete Therapeutics
  • Mailing Address
    7000 Shoreline Court South San Francisco, CA 94080
  • Company Description
    Arête Therapeutics Inc. is discovering and developing ‘first in class’ small molecule drugs directed at novel targets for cardiovascular diseases and inflammation. The Company’s proprietary therapies are directed at a new branch of arachidonic acid metabolism, which is a proven (US $10+B) pathway for therapeutic intervention in a variety of inflammatory diseases.
  • Website
    http://www.aretetherapeutics.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $13,300,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    Dinesh V. Patel, Ph.D.,president and chief executive officer of Arête Therapeutics Inc. said, “This financing, with anexceptional group of top tier investors, will allow us to advance our product portfolio andachieve clinical proof of concept in humans. We anticipate initiating clinical trials for our firstIND candidate, AR9281, by the end of 2007.”
  • M&A Terms
  • Venture Investor
    Frazier Healthcare Ventures
  • Venture Investor
    Alta Partners
  • Venture Investor
    Three Arch Partners
  • Venture Investor
    Burrill & Company
  • Venture Investor
    Altitude Capital Partners

By posting a comment, you agree to our terms and conditions.